Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Oncternal Therapeutics Inc. diskutieren

Oncternal Therapeutics Inc.

WKN: A2PL3P / Symbol: ONCT / Name: Oncternal Therapeutics / Aktie / Small Cap /

0,32 €
4,71 %

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its "buy" rating re-affirmed by analysts at Brookline Capital Management.
Ratings data for ONCT provided by MarketBeat

Einschätzung Buy
Rendite (%) -55,62 %
Kursziel 8,34
Veränderung
Endet am 22.03.24

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $14.00 to $9.00. They now have an "outperform" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Der Beitrag wird untersucht

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat

Einschätzung Buy
Rendite (%) 3,23 %
Kursziel 1,85
Veränderung
Endet am 04.12.24

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock.
Ratings data for ONCT provided by MarketBeat

Oncternal Therapeutics, Inc. (NASDAQ: ONCT) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for ONCT provided by MarketBeat